The company sells products directly and through third-party distributors to hospital microbiology laboratories domestically and internationally. Clinical data demonstrates significant clinical outcomes, including a statistically significant reduction in 30-day mortality for patients receiving faster diagnostic results.
Cyborg Score Rationale
The company operates in a high-value diagnostic niche with proven clinical utility, but faces significant commercialization challenges evidenced by minimal revenue (~$11.7M TTM) relative to its market cap. Stock price volatility and small employee base (107) suggest operational stress and limited scale.
Top Insights
Clinical evidence shows 6.0% mortality with Accelerate Pheno vs. 15.9% with standard care for bloodstream infections, demonstrating compelling clinical value
Revenue of $11.69M TTM (as of January 2026) remains substantially below market expectations for a diagnostic platform company
Company operates with only 107 employees under CEO Jack Phillips
Stock trading at highly depressed valuations with significant delisting risk given market cap pressures
Named Competitors
MALDI Biotyper — Mass spectrometry-based microbial identification
BD Phoenix — Automated microbiology identification and susceptibility testing
Vitek 2 — Automated microbial identification and antimicrobial susceptibility testing
Recent Developments
(April 2026) Financial data updated through Q1 2026 showing TTM revenue of $11.69M
(March 2026) Scheduled earnings release on March 26, 2026
(Q4 2024) Reported EPS of -$0.37, beating loss estimates of -$0.50
Open the full interactive Accelerate Diagnostics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.